• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

纯合基因突变导致肺部受累的囊性纤维化:一例报告

Cystic fibrosis caused by homozygous gene mutation leading to pulmonary involvement: a case report.

作者信息

Duan Ji-Peng, Dai Ru-Fen, Ma Wan-Hong, Luo Tian-Shu, Duan Zhi-Zhen, Zhang Xue-Fen, Zhang Yan-Ling, Liu Ming-Wei

机构信息

Department of Respiratory and Critical Care Medicine, People's Hospital of Dali Bai Autonomous Prefecture Dali 671000, Yunnan, China.

Department of Emergency, People's Hospital of Dali Bai Autonomous Prefecture Dali 671000, Yunnan, China.

出版信息

Am J Transl Res. 2025 May 15;17(5):3813-3823. doi: 10.62347/ENOM2926. eCollection 2025.

DOI:10.62347/ENOM2926
PMID:40535643
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12170377/
Abstract

Cystic fibrosis (CF) is an autosomal recessive monogenic disorder caused by mutations in the CF transmembrane conductance regulator () gene, resulting in impaired protein function. Predominantly affecting Caucasians, CF involves multiple organ systems, including the lungs, pancreas, liver, gastrointestinal tract, and reproductive system. In contrast, CF remains rare among Asian populations, particularly within the Chinese demographic. Reported cases in China predominantly feature heterozygous mutations, with no confirmed instances of homozygous mutations. A 15-year-old male presented with a 6-year history of recurrent cough and purulent yellow-green sputum production, without hemoptysis. Whole exome sequencing identified a homozygous mutation, NM_000492.4:c.2290C>T (p.Arg764*), confirming the diagnosis of CF complicated by pulmonary infection. The patient received intravenous cefoperazone/sulbactam (2.25 g every 12 hours) and moxifloxacin (400 mg once daily). Symptomatic improvement was achieved after 2 weeks, and azithromycin was prescribed (three times weekly) upon discharge. This case highlights the importance of considering gene mutations in patients with prolonged respiratory symptoms (recurrent cough and sputum production) and imaging findings indicative of pulmonary CF. Whole exome sequencing is recommended to determine the genetic etiology in such cases and guide targeted management.

摘要

囊性纤维化(CF)是一种常染色体隐性单基因疾病,由囊性纤维化跨膜传导调节因子(CFTR)基因突变引起,导致CFTR蛋白功能受损。CF主要影响白种人,累及多个器官系统,包括肺、胰腺、肝脏、胃肠道和生殖系统。相比之下,CF在亚洲人群中仍然罕见,尤其是在中国人群中。中国报告的病例主要为杂合CFTR基因突变,尚无纯合突变的确诊病例。一名15岁男性有6年反复咳嗽和咳出黄绿脓性痰的病史,无咯血。全外显子组测序确定了一个纯合CFTR基因突变,NM_000492.4:c.2290C>T(p.Arg764*),确诊为CF合并肺部感染。患者接受静脉注射头孢哌酮/舒巴坦(每12小时2.25 g)和莫西沙星(每日一次400 mg)。2周后症状改善,出院时开具阿奇霉素(每周三次)。该病例强调了对于有长期呼吸道症状(反复咳嗽和咳痰)且影像学表现提示肺部CF的患者,考虑CFTR基因突变的重要性。建议进行全外显子组测序以确定此类病例的遗传病因并指导针对性治疗。

相似文献

1
Cystic fibrosis caused by homozygous gene mutation leading to pulmonary involvement: a case report.纯合基因突变导致肺部受累的囊性纤维化:一例报告
Am J Transl Res. 2025 May 15;17(5):3813-3823. doi: 10.62347/ENOM2926. eCollection 2025.
2
Impact of elexacaftor/tezacaftor/ivacaftor on the small airways in cystic fibrosis.依列卡福妥/替扎卡福妥/依伐卡托对囊性纤维化患者小气道的影响。
J Bras Pneumol. 2025 Jun 13;51(2):e20240406. doi: 10.36416/1806-3756/e20240406. eCollection 2025.
3
Risk of Pancreatic Cancer in Cystic Fibrosis and Cystic Fibrosis Transmembrane Conductance Regulator Germline Variants: A Retrospective Cohort Study.囊性纤维化及囊性纤维化跨膜传导调节因子种系变异与胰腺癌风险:一项回顾性队列研究
Clin Transl Gastroenterol. 2025 May 27. doi: 10.14309/ctg.0000000000000857.
4
[Chinese experts consensus statement: diagnosis and treatment of cystic fibrosis (2023)].[中国专家共识声明:囊性纤维化的诊断与治疗(2023年)]
Zhonghua Jie He He Hu Xi Za Zhi. 2023 Apr 12;46(4):352-372. doi: 10.3760/cma.j.cn112147-20221214-00971.
5
Diseases Common in Persons With Cystic Fibrosis Among CFTR Heterozygotes.CFTR杂合子中囊性纤维化患者常见的疾病。
JAMA Intern Med. 2025 Jun 16. doi: 10.1001/jamainternmed.2025.1853.
6
Impact of Cystic Fibrosis Transmembrane Conductance Regulator Modulators on Maternal Outcomes During and After Pregnancy.囊性纤维化跨膜传导调节因子调节剂对孕期及产后母体结局的影响。
Chest. 2025 Feb;167(2):348-361. doi: 10.1016/j.chest.2024.09.019. Epub 2024 Sep 27.
7
Evolving nutrition therapy in cystic fibrosis: Adapting to the CFTR modulator era.囊性纤维化中不断发展的营养治疗:适应CFTR调节剂时代。
Nutr Clin Pract. 2025 Aug;40(4):816-828. doi: 10.1002/ncp.11332. Epub 2025 Jun 18.
8
A novel follicle-stimulating hormone receptor mutation causing primary ovarian failure: a fertility application of whole exome sequencing.一种导致原发性卵巢功能衰竭的新型促卵泡激素受体突变:全外显子组测序在生育方面的应用
Hum Reprod. 2016 Apr;31(4):905-14. doi: 10.1093/humrep/dew025. Epub 2016 Feb 23.
9
CRISPR for cystic fibrosis: Advances and insights from a systematic review.用于囊性纤维化的CRISPR:系统评价的进展与见解
Mol Ther. 2025 Jun 17. doi: 10.1016/j.ymthe.2025.06.021.
10
Renal hydatid cyst mimicking malignancy: a case report.酷似恶性肿瘤的肾包虫囊肿:一例报告
Int J Surg Case Rep. 2025 Jul;132:111506. doi: 10.1016/j.ijscr.2025.111506. Epub 2025 Jun 13.

本文引用的文献

1
Enrichment of rare CFTR variants in Finnish patients with congenital chloride diarrhea.芬兰先天性氯腹泻患者中罕见CFTR变异的富集情况。
PLoS One. 2025 Feb 24;20(2):e0318249. doi: 10.1371/journal.pone.0318249. eCollection 2025.
2
Discovery and Development of CFTR Modulators for the Treatment of Cystic Fibrosis.用于治疗囊性纤维化的CFTR调节剂的发现与开发
J Med Chem. 2025 Feb 13;68(3):2255-2300. doi: 10.1021/acs.jmedchem.4c02547. Epub 2025 Jan 30.
3
Current landscape of cystic fibrosis gene therapy.囊性纤维化基因治疗的现状
Front Pharmacol. 2024 Oct 8;15:1476331. doi: 10.3389/fphar.2024.1476331. eCollection 2024.
4
Pharmacological and pre-clinical safety profile of rSIV.F/HN, a hybrid lentiviral vector for cystic fibrosis gene therapy.用于囊性纤维化基因治疗的杂交慢病毒载体rSIV.F/HN的药理学和临床前安全性概况
Eur Respir J. 2025 Jan 30;65(1). doi: 10.1183/13993003.01683-2023. Print 2025 Jan.
5
Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants (most commonly F508del).针对携带 II 类 CFTR 基因突变(最常见的是 F508del)的囊性纤维化患者的校正治疗(有或没有增效剂)。
Cochrane Database Syst Rev. 2023 Nov 20;11(11):CD010966. doi: 10.1002/14651858.CD010966.pub4.
6
Elexacaftor-Tezacaftor-Ivacaftor Therapy for Chronic Sinus Disease in Cystic Fibrosis.依伐卡托与泰他卡托和艾克卡托三联组合药物治疗囊性纤维化慢性鼻窦病。
JAMA Otolaryngol Head Neck Surg. 2023 Dec 1;149(12):1075-1082. doi: 10.1001/jamaoto.2023.2701.
7
Cystic fibrosis: Epidemiology, clinical manifestations, diagnosis and treatment.囊性纤维化:流行病学、临床表现、诊断与治疗。
Med Clin (Barc). 2023 Nov 10;161(9):389-396. doi: 10.1016/j.medcli.2023.06.006. Epub 2023 Aug 7.
8
Clinical and genetic characteristics of children with cystic fibrosis in Henan China: A single-center retrospective analysis.中国河南地区囊性纤维化患儿的临床和遗传学特征:一项单中心回顾性分析。
Pediatr Pulmonol. 2023 Oct;58(10):2865-2870. doi: 10.1002/ppul.26601. Epub 2023 Jul 21.
9
Cystic Fibrosis: A Review.囊性纤维化:综述。
JAMA. 2023 Jun 6;329(21):1859-1871. doi: 10.1001/jama.2023.8120.
10
Cystic Fibrosis Modulator Therapies.囊性纤维化调节剂疗法
Annu Rev Med. 2023 Jan 27;74:413-426. doi: 10.1146/annurev-med-042921-021447. Epub 2022 Aug 16.